Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
SEATTLE, Jan. 7, 2025 /PRNewswire/ -- Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for...
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
Jan 7, 2025 · Variant Bio, a genomics-driven drug discovery company, today announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
Jan 7, 2025 · The partnership between Novo Nordisk and Variant Bio is aimed at identifying and validating multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.
Novo inks $50M metabolic disease pact with genomics biotech
Jan 7, 2025 · Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse...
Seattle startup lands deal with Novo Nordisk to study obesity
Jan 7, 2025 · Variant Bio today announced a partnership with Novo Nordisk for disease research and development that could total $50 million for the biotech startup. The Seattle company is working with...
Variant Bio and Novo Nordisk to identify targets for metabolic …
Jan 7, 2025 · Leveraging Variant’s ‘VB-Inference analysis’ platform, which integrates whole genomes with multi-omic data to map disease mechanisms, the collaboration aims to identify targets with...
Collaborations | Variant Bio
Jan 7, 2025 · Variant Bio has launched a multi-year research collaboration with Novo Nordisk to identify and validate novel targets with strong genetic evidence for the treatment of metabolic disease.
Variant Bio and Novo Nordisk sign multi-year research …
Variant Bio has announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease. The partnership is aimed at identifying and validating multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programmes.
Variant Bio Announces Multi-Year Research Partnership with Novo Nordisk …
Jan 7, 2025 · The multi-year target discovery collaboration announced signals a new chapter of growth for Variant Bio. The strategic partnership with Novo Nordisk demonstrates the value of Variant Bio's potential to enable the development of novel therapeutics based on results from its innovative genomic studies.
Variant Bio Partners with Novo Nordisk to Discover Novel …
Jan 7, 2025 · The partnership between Novo Nordisk and Variant Bio is aimed at identifying and validating multiple novel targets with sufficient human genetic evidence to initiate human-centric drug discovery programs.